Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.

Kohei KakuMasakazu HanedaYuko TanakaGanghyuck LeeKosuke ShikiYuki MiyamotoFernando SolimandoJisoo LeeChristopher LeeJyothis George

Published in: Diabetes, obesity & metabolism (2018)

These results support Empa/Lina FDC as a potential option for Japanese patients with T2DM who require combination therapy. ClinicalTrials.gov NCT02489968.

Keyphrases

combination therapy
double blind
placebo controlled
type diabetes
open label
clinical trial
phase iii
phase ii
study protocol
randomized controlled trial
human health
risk assessment
adipose tissue
metabolic syndrome
climate change
weight loss